The SBCC facility is capable of handling the synthesis of all small to large organic molecules as well as biopolymers such as DNA, RNA and peptides.
In each of these areas, the appropriate SBCC co-director will engage the research PI and staff regarding consultation and formulation of the initial design and subsequent execution to ensure the successful completion of the project.
State-of-the-art organic synthesis and the use of modern synthetic methodologies are employed for the efficient construction of molecular agents and ligands. The SBCC is committed to advancing collaborative research efforts through creation of a multidisciplinary team approach to chemical biology and drug discovery.
The following is a list of specific services and capabilities currently supported by the Synthetic and Biopolymer Chemistry Core facility:
- This includes synthesis of commercially unavailable reagents such as derivatives of modified and/or labeled nucleosides.
- Examples include specialized covalent and none-covalent (Watson-Crick) conjugates of various biopolymers, for example: siRNA-aptamers or DNA-peptide hybrid derivatives.
- Examples include peptides containing phosphorylated serine/threonine/tyrosine residues, acetylated lysines, as well as biotin, fluorescein, D-amino acids, 13C and 15N labeled amino acids and other unusual moieties.
- This is particularly applicable for the production and isolation of large amounts of very pure RNA and DNA. Examples include chimeric ribozymes and siRNAs modified with cholesterol, which are used in animal studies, as well as large amounts of DNA for NMR structural studies.
- This encompasses natural and non-natural analogs of carbocycles, heterocycles, carbohydrates, terpenoids, steroids, small peptides, and peptide mimetics as well as nanoparticle derivatives.
- This is accomplished in close collaboration with the HTS Core and structural biophysical groups in the City of Hope Cancer Center that include NMR, X-ray, and molecular modeling.
- An international collaborative effort is underway in conjunction with the Strathclyde Institute (Scotland, UK) to identify anti-cancer natural products from terrestrial sources around the world (vida infra).
- Full in-house capabilities are in place for scale-up synthesis of optimized lead candidates for use in chemical biology studies and pre-clinical evaluation.
- This will be accomplished in conjunction with the pharmacology group for metabolic identification studies.
- Libraries are used for the identification and optimization of lead compounds.
- The objective is to work in close collaboration with biologists toward new and improved enzyme/protein assay development yielding more efficient, accurate, and reliable results.
- This includes the design and synthesis of new ligands and the synthesis of radiolabeled substrates in conjunction with cancer immunotherapeutics researchers.